Clinical Trial Update: Impact of Empaglifozine on Cardiac Ectopic Fat [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating empagliflozin on cardiac ectopic fat in type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Assistance Publique Hopitaux De Marseille | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED